ABBV vs AMGN
AbbVie and Amgen, both Healthcare
AbbVie is the larger company at $505B against $237B. On trailing earnings AMGN is the cheaper of the two at a P/E of 27.3 against 80.7, a gap that is only a bargain if the two are growing at similar rates. Over the past year AMGN returned +52% against +28% for ABBV. The RyuScore puts AMGN ahead, 62 against 48 out of 100.
| Figure | ABBV | AMGN |
|---|---|---|
| Last close | $286 | $439 |
| Market cap | $505B | $237B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 80.7 | 27.3 |
| Dividend yield | 2.3% | 2.2% |
| 1-year return | +28% | +52% |
| 5-year return | +209% | +147% |
| RyuScoresector-relative, 1–10 | 48/100 | 62/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AbbVie
Revenue of $17B in Q2 2026, net income $3.6B. Its largest reported line is SKYRIZI, 36% of the disclosed total.
Amgen
Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.